This morning, Citigroup raised its price target on shares of Endo Pharmaceuticals (ENDP) to $48 following an encouraging management meeting. With the higher price target, Citigroup maintained its buy rating.
Shares of Endo Pharmaceuticals lower on Thursday, falling just about 1%.
And Morgan Stanley increased its EPS estimates on shares of Fastenal (FAST) through 2012 as improving margins should trickle down to the bottom line. In the report, Morgan Stanley maintained its underweight rating, but moved its price target higher to $60 per share.
Fastenal shares were flat on the news, falling just a few pennies, but trading above Morgan Stanley's price target.
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.